The safety of bevacizumab

Expert Opinion on Drug Safety
Rachel E Sanborn, Alan B Sandler

Abstract

Despite the significant gains made in the treatment of many cancers over the last few decades, further improvements in survival using traditional chemotherapeutic agents have now begun to plateau. The development of bevacizumab, a monoclonal antibody targeted against the vascular endothelial growth factor, has provided promise for continued gains in survival in the therapy of a variety of cancers, including some previously refractory to traditional chemotherapeutic agents. Although its toxicity profile differs from traditional chemotherapeutic drugs, bevacizumab is not completely without side effects. The mechanisms of its unique toxicities have not yet been fully characterised, and at this time it is not possible to predict which toxicities will be experienced by each individual patient or which population.

References

Oct 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·R MontesanoL Orci
Jan 23, 1987·Science·J Folkman, M Klagsbrun
Jan 1, 1987·Nouvelle Revue Française D'hématologie·A Camez, G Tobelem
Nov 1, 1989·The Journal of Clinical Investigation·D T ConnollyJ Feder
Aug 12, 1971·The New England Journal of Medicine·J Folkman
Feb 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K MaedaY Arimoto
Sep 30, 1993·International Journal of Cancer. Journal International Du Cancer·M ToiT Tominaga
Feb 20, 1997·International Journal of Cancer. Journal International Du Cancer·M VolmJ Mattern
Oct 3, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S BhatiaL H Einhorn
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S GordonD Adelman
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz KabbinavarEmily Bergsland
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David H JohnsonFairooz Kabbinavar
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz F KabbinavarWilliam F Novotny
Oct 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthAnthony Greco

❮ Previous
Next ❯

Citations

May 16, 2007·Cancer Immunology, Immunotherapy : CII·Debra KamstockSteven Dow
Feb 3, 2007·Current Opinion in Oncology·Fiona H Blackhall, Frances A Shepherd
Oct 24, 2006·The British Journal of Ophthalmology·S Michels
Nov 12, 2010·Breast Cancer Research : BCR·Dorte Lisbet NielsenClaus Kamby
Mar 5, 2014·Expert Opinion on Drug Safety·Shuang ZhangYuquan Wei
Jun 15, 2011·Expert Opinion on Drug Safety·Iben Kümler, Dorte Lisbet Nielsen
Feb 28, 2007·Critical Reviews in Oncology/hematology·Robert Roskoski
Sep 13, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leo MascarenhasDouglas S Hawkins
Mar 19, 2008·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·James E Frampton, Gillian M Keating

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.